Categories
Change Password!
Reset Password!
This retrospective cohort study compared the major adverse cardiovascular events (MACE) and all-cause mortality between xanthine oxidase inhibitors (XOIs) and non-XOI users, and allopurinol and febuxostat users.
In this study of total 13,997 gout patients, no benefit of XOI use on risk of major
cardiovascular events or all-cause mortality was found; febuxostat had a
similar risk of cardiovascular events and all-cause mortality than with
allopurinol; concomitant colchicine use
decrease all-cause mortality risk among
XOI users and its > 3 days use significantly reduces hospitalizations due to
heart failure.
This retrospective cohort
study compared the major adverse
cardiovascular events (MACE) and all-cause mortality between xanthine oxidase
inhibitors (XOIs) and non-XOI users, and allopurinol and febuxostat users.
The propensity scores was used to match XOI users 1:1 to XOI non-users in gout patients under consideration. Febuxostat users were matched 1:3 to allopurinol users. As per colchicine use, the subgroup analyses were directed.
Overall, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users out of total 13 997 eligible gout patients. XOI users (n = 3607) showed similar incidence of MACE and all-cause mortality as compared to non-users (n = 3607), Table 1.
Febuxostat (n = 276) users portrayed a similar risk of MACE than with allopurinol users with an inclination towards lower heart failure-related hospitalizations risk, Table 2.
The use of concomitant colchicine decreased
the risk for all-cause mortality in XOI users.
A similar risk profile of MACE and
all-cause mortality was observed XOI users and non-users in gout patients.
Paitents using febuxostat had similar MACE and all-cause mortality risks
nevertheless lower heart failure-related hospitalizations as compared to
allopurinol.
Europe PMC
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C et al.
Comments (0)